Introduction
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.
Information is being updated
You need to login to view information
Charter capital
Business Size and Operations
Company Size
Total Assets
| A10 (Bellow 100 B) | A9 (100 - 200 B) | A8 (200 - 400 B) | A7 (400 - 600 B) | A6 (600 - 800 B) |
| A5 (800 - 1000 B) | A4 (1000 - 1500 B) | A3 (1500 - 2000 B) | A2 (2000 - 2500 B) | A1 (Above 2500 B) |
Owner’s Equity
| E10 (Bellow 100 B) | E9 (100 - 200 B) | E8 (200 - 400 B) | E7 (400 - 600 B) | E6 (600 - 800 B) |
| E5 (800 - 1000 B) | E4 (1000 - 1500 B) | E3 (1500 - 2000 B) | E2 (2000 - 2500 B) | E1 (Above 2500 B) |
Business Activities
Revenue
| R10 (Bellow 100 B) | R9 (100 - 200 B) | R8 (200 - 400 B) | R7 (400 - 600 B) | R6 (600 - 800 B) |
| R5 (800 - 1000 B) | R4 (1000 - 1500 B) | R3 (1500 - 2000 B) | R2 (2000 - 2500 B) | R1 (Above 2500 B) |
Number of employee
| L10 (Bellow 100 Peoples) | L9 (100 - 200 Peoples) | L8 (200 - 400 Peoples) | L7 (400 - 600 Peoples) | L6 (600 - 800 Peoples) |
| L5 (800 - 1000 Peoples) | L4 (1000 - 1500 Peoples) | L3 (1500 - 2000 Peoples) | L2 (2000 - 2500 Peoples) | L1 (Above 2500 Peoples) |
Company’s Market Position
Profitability within the Industry
Return on Total Assets (ROA)
| Bottom 25% | 25%-m | m-25% | Top 25% |
Return on Equity (ROE)
Net Profit Margin (ROS)
Current Ratio
| Bottom 25% | 25%-m | m-25% | Top 25% |
Total asset turnover
| Bosttom 25% | 25%-m | m-25% | Top 25% |